OPEN END TURBO OPTIONSSCHEIN SHORT - VERTEX PHARMACEUTICALS | Real-time BOERSE MUENCHEN 19:26:26 06/06/2024 BST | ||
| 11.18 EUR | +0.72% |
|
| Current month | -20.09% | ||
| 1 month | -38.94% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 06/06/24 | 11.18 | +0.72% |
| 05/06/24 | 11.1 | -5.45% |
| 04/06/24 | 11.74 | -5.70% |
| 03/06/24 | 12.45 | -11.01% |
| 31/05/24 | 13.99 | -6.30% |
Real-time BOERSE MUENCHEN
Last update June 06, 2024 at 07:26 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GG7EDH |
| ISIN | DE000GG7EDH1 |
| Date issued | 23/04/2024 |
| Strike | 600.8 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 18.84 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 19.4 € |
|---|---|
| Lowest since issue | 10.94 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
485.5
USD
Average target price
463.5
USD
Spread / Average Target
-4.53%
- Stock Market
- Certificates
- Certificat